Early cancer detection could save millions of lives and billions of dollars a year. But without low-cost, high-performing, convenient tests, cancer screening rates have remained alarmingly low.
Recent advances in our understanding of cancer DNA and machine learning allow DELFI to dramatically reduce the cost of screening tests while increasing performance. Read More >>
DELFI’s leadership team includes leading experts in cancer biology, bioinformatics, and machine learning. Meet the Team >>